Vivoryon Pursues Varoglutamstat Partnerships, Cuts Costs; Q3 Results Set for Nov. 5

Vivoryon Therapeutics said it is in advanced negotiations with multiple parties over partnerships for varoglutamstat in kidney disease and has implemented additional cost-saving measures. It will report third-quarter 2026 results on November 5, 2026, with a business update and updated cash runway guidance.